ABSTRACT
The technical and physiologic shortcomings associated with prior generations of polymethylmethacrylate (PMMA) dermal fillers have been reduced significantly since their original market introduction in 1989. For example, the PMMA microspheres in the third-generation product ArteFill meet the new limit set by the FDA of less than 1 particle below 20 micrometers per 100 microspheres (< 1% by the number). Therefore, it is expected that the already low granuloma rate following injections with second-generation product Artecoll (1:5000) will be reduced further with injections of ArteFill. In the authors' experience, both Artecoll and ArteFill have proven to be safe, predictable, and effective dermal fillers. It is anticipated that Artefill will receive FDA approval in late 2006 and will be marketed internationally.
